← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Gigamune, Inc.
San Francisco, CA
$2,750,294
Total funding
8
Grants
Funding over time
peak $800K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,750,294 · 8
By mechanism
R43$2,350,294 · 7
R44$400,000 · 1
Investigators at Gigamune, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Engineered TCR-T Cell Therapy Targeting Driver Mutations in NSCLC$400,000
R43 · FY2021 · CA
A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma$400,000
R44 · FY2025 · CA
Engineered TCR-T Cell Therapies Targeting Shared Tumor Associated Antigens$400,000
R43 · FY2021 · CA
In vivo Gene Delivery to Regulatory T Cells to Drastically Reduce the Cost of Regulatory T Cell Therapy$300,000
R43 · FY2023 · AI
Engineered TCR-Treg Cell Therapies Targeting Type 1 Diabetes Autoantigens$300,000
R43 · FY2022 · AI
In vivo Sickle Cell Disease Gene Therapy Using a Novel Virus Like Particle$300,000
R43 · FY2024 · HL
Recombinant TIL Cell Therapy for Salvage Solid Tumor Patients$300,000
R43 · FY2018 · CA
Delivery of Full Length Dystrophin to Muscle Cells for DMD Gene Therapy$295,294
R43 · FY2023 · AR
Engineered TCR-Treg Cell Therapies Targeting Type 1 Diabetes Autoantigens$55,000
R43 · FY2023 · AI